Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature.

Autor: Ruiz-Bañobre J; Servizo de Oncoloxía Médica & Grupo de Oncoloxía Médica Traslacional, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela, Spain. Electronic address: jurruba@gmail.com., Pérez-Pampín E; Servizo de Reumatoloxía, Complexo Hospitalario Universitario de Santiago de Compostela, Spain; Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela, Spain., García-González J; Servizo de Oncoloxía Médica & Grupo de Oncoloxía Médica Traslacional, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela, Spain., Gómez-Caamaño A; Servizo de Oncoloxía Radioterápica, Complexo Hospitalario Universitario de Santiago de Compostela, Spain., Barón-Duarte FJ; Servizo de Oncoloxía Médica & Grupo de Oncoloxía Médica Traslacional, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela, Spain., López-López R; Servizo de Oncoloxía Médica & Grupo de Oncoloxía Médica Traslacional, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela, Spain., Vázquez-Rivera F; Servizo de Oncoloxía Médica & Grupo de Oncoloxía Médica Traslacional, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela, Spain.
Jazyk: angličtina
Zdroj: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2017 Jun; Vol. 108, pp. 217-221. Date of Electronic Publication: 2017 Apr 14.
DOI: 10.1016/j.lungcan.2017.04.007
Abstrakt: Lung cancer is the leading cause of cancer-related death worldwide. The most common type, non-small cell lung cancer (NSCLC), is further divided into two main types, squamous cell and non-squamous cell (which includes adenocarcinoma). Nivolumab, a fully human IgG4 programmed death-1 immune checkpoint inhibitor antibody, has shown not only an overall survival advantage when compared to docetaxel, but also a relatively good side-effect profile among patients with previously treated advanced squamous and non-squamous NSCLC. Psoriatic arthritis (PsA), a heterogeneous chronic inflammatory disease, has a wide clinical spectrum and a variable clinical course that affects mainly musculoskeletal structures, skin and nails. Here we report the second case to the best of our knowledge of PsA development during nivolumab therapy. It is important to note that arthritis activity decreased without nivolumab discontinuation with the use of naproxen and a low dose of corticosteroid. Furthermore, a minimal disease activity was achieved adding methotrexate to the treatment and antitumor therapy efficacy was not influenced (a partial response was documented after eight and 39 cycles of nivolumab). Rheumatic immune-related adverse events management is a challenge and a coordinated multidisciplinary management by medical oncologists, rheumatologists and immunologists will be mandatory in the near future.
(Copyright © 2017 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: